<DOC>
	<DOCNO>NCT00294554</DOCNO>
	<brief_summary>The purpose research evaluate usefulness memantine , compare placebo ( sugar pill ) , treatment cognitive impairment patient idiopathic Parkinson 's disease ( PD ) dementia . Memantine use safe effective treatment patient Alzheimer 's disease . Cognitive impairment include concentration memory difficulty . We look well medication help cognitive impairment , well tolerate medication ( include effect motor symptom PD ) activity daily live , emotion , medical condition might . We interview person choose `` informant '' .</brief_summary>
	<brief_title>Memantine Treatment Cognitive Impairment Patients With Parkinson 's Disease Dementia</brief_title>
	<detailed_description>This randomize , placebo-controlled , parallel , double-blind 24-week prospective study memantine dosage range 5-20 mg/day 20 outpatient idiopathic PD dementia secondary PD . Using dosage escalation regimen approve Alzheimer disease , subject start memantine comparable placebo 5 mg daily advance 5 mg/week 20 mg /day week 4 , dose 10 mg bid . Subjects undergo 7 clinical visit 6-month trial ( Screen , Baseline/Week 0 , Weeks 4 , 8 , 14 , 20 , 24 ) . The dosage titrate downward increment 5 mg minimum dose 5 mg/day event memantine tolerate scheduled dosage . This broad dose range use 1 ) favorable cognitive response may evident low dos memantine recommend AD 2 ) adverse effect could emerge typical AD dosing recommendation use , observe treat PD patient cholinesterase inhibitor . Subjects remain stable dose memantine/placebo Week 8 , unless precluded adverse event . Ten subject assign treatment group . Randomization stratify accord whether subject take concomitant cholinesterase inhibitor . This enable secondary group comparison treatment group . Results initial small study use evaluate appropriateness devise larger-scale multi-site study memantine treatment dementia PD . The proposed assessment schedule design represent use memantine general clinical practice minimize burden caregiver patient , impaired mobility well cognitive function .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Diagnosis idiopathic PD , define UK Brain Bank Criteria . 2 . Age onset PD &gt; 35 year old 3 . Adult men woman , current age &gt; 50 year 4 . English speak 5 . Any race ethnic background . 6 . Hoehn Yahr Stage IV , provide able participate verbally clinical assessment travel clinic . 7 . Diagnosis dementia secondary PD , define DSMIVTR . 8 . Stable medical health 9 . Taking stable dos 2 month nonexcluded medication . 10 . Outpatient status ( may reside longterm care facility ) . 11 . Able attend study visit inform caregiver/partner willing provide information patient 's clinical status response treatment . 12 . Presence inform caregiver willing take part weekly phone call followup call duration study enrollment . 13 . Provision informed consent patient caregiver and/or legal guardian . 14 . On stable antiparkinsonian therapy 2 month . 15 . If history major depression anxiety disorder , must stable symptom stable therapy 2 month . 16 . If take antipsychotic medication , must stable therapy 2 month . 17 . If take nonsteroidal antiinflammatory medication , selegiline , estrogen , must stable dose 30 day study entry . 18 . If take cholinesterase inhibitor , must least 6 month stable dose 2 month randomization . 1 . History evidence neurodegenerative disorder PD . 2 . Meets clinical criterion Dementia Lewy Bodies . 3 . History current evidence epilepsy . 4 . Participation another investigational drug trial within 2 month screen . 5 . Treatment memantine within 60 day screen . 6 . Current symptomatic Major Depressive Disorder , base Hamilton Depression Rating Scale Score &gt; 17 . 7 . Current clinically significant hepatic , kidney disease , gastrointestinal , endocrine , cardiovascular disease , include evidence second third degree heart block . [ Note , patient control hypertension ( supine diastolic BP &lt; 95 mm Hg ) , complete partial right bundle branch block , pacemaker , deep brain stimulators may include . ] .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Cognitive Impairment</keyword>
	<keyword>Dementia</keyword>
	<keyword>Memory</keyword>
</DOC>